There is little evidence to suggest that the use of DMARDs is associated with worsening of RA-ILD, although tumour necrosis factor (TNF)-alpha inhibitors may be associated with higher mortality than other DMARDs [41, 42]. Here, TNF is linked to interstitial lung disease.